GSK · Pharma and healthcare · one day
GSK (GSK): news on Saturday 31 October 2026
News from the 24 hours to Saturday morning, 31 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on third-quarter results, where earnings beat expectations and the dividend was confirmed, with specialty medicines offsetting weaker vaccines. Sentiment leans positive on a broker upgrade, a higher price target and a share price rise, tempered by a Barclays sell rating and questions over falling earnings.
What drove it
- Q3 results
- analyst ratings
- share price rise
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
| Tue 27 Oct | +9.3 | 29 |
| Wed 28 Oct | +7.0 | 23 |
| Thu 29 Oct | −6.3 | 77 |
| Fri 30 Oct | −3.7 | 21 |
| Sat 31 Oct | +4.0 | 12 |
5 stories · 12 headlines · strongest first
Pharma and healthcare on 31 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK reports third-quarter results, keeps 2026 outlook; shares fall on vaccines −2.66 headlines today · 88 in all, since 24 October · Coverage notes GSK beat earnings and confirmed its dividend, with specialty medicines offsetting weaker vaccines. | ||
| +9.2 | Profit beat expectations and dividend was maintained. | |
| −4.7 | Analysis questions whether declining earnings weaken the investment argument. | |
| +2.5 | Analyst post-results review, broadly balanced view. | |
| +2.0 | Specialty medicines growth cushions softer vaccine sales in quarterly results. | |
| +2.0 | Specialty medicines growth cushions softer vaccine sales in quarterly results. | |
| −1.3 | Earnings roundup describes it as in a holding pattern versus peers. | |
| Broker ratings on GSK +2.73 headlines today · Barclays has a Sell rating, AlphaValue/Baader upgraded to Buy and a target was raised. | ||
| +8.5 | Broker raised its recommendation to buy. | |
| −7.3 | Barclays holds a negative recommendation on the shares. | |
| +7.0 | Higher analyst price target points to meaningful potential gains. | |
| GSK shares rise 2.3% +7.71 headline today · A piece asks what is behind GSK's 2.3% share surge. | ||
| +7.7 | Shares rose sharply on the day. | |
| FDA clears Hibsago, GSK's medicine for chronic hepatitis B +10.01 headline today · 48 in all, since 21 October · A newsletter mentions the hepatitis B approval for GSK. | ||
| +6.3 | Regulatory approval for its hepatitis B treatment mentioned. | |
| Pharma as defensive investment +2.31 headline today · A piece looks at pharma shares including GSK as defensive. | ||
| +2.3 | Named among pharma shares as a defensive option, alongside others. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.